Please assess the completion status of the following clinical trial:

Trial Title: AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of IPF~* Age between 35 and 80, inclusive~* Capable of understanding and signing consent~* Progression despite conventional therapy (standard of care). Progression defined as:~  1. Worsened dyspnea~ 2. FVC decreased by \>=10% predicted OR~ 3. DLCO decreased by \>=10% absolute OR~ 4. Reduction of oxygenation saturation \>= 5% with or without exertion on a constant oxygen (02) administration~ 5. Worsened radiographic findings (chest x-ray or high-resolution computed tomography)~Exclusion Criteria:~* Current enrollment in another investigational protocol~* Current treatment with an investigational drug (i.e., participating in an active investigational drug protocol) within the previous 4 weeks or 5 times the half-life of the investigational agent, whichever is longer, prior to screening~* Subject is actively listed for lung transplantation at the time of enrollment~* Subjects who will not be able to perform/complete the study, in the judgment of the physician investigator or coordinator, for at least 3 months. For example:~  1. Subject has current signs or symptoms of severe, progressive or uncontrolled comorbid illnesses such as: renal, hepatic, hematologic, gastrointestinal, endocrine, cardiac, neurologic, or cerebral disease, or any laboratory abnormality which would pose/suggest a risk to the subject during participation in the study.~ 2. Subject has a transplanted organ requiring immunosuppression~ 3. History of substance abuse (drugs or alcohol) within the 2 years prior to screening, history of noncompliance to medical regimens, inability or unwillingness to perform INR monitoring, or other condition/circumstance that could interfere with the subject's adherence to protocol requirements (e.g. psychiatric disease, lack of motivation, travel, etc).~ 4. Have any known active malignancy or have a history of malignancy within the previous 2 years (an example of an exception is a non-melanoma skin cancer that has been treated with no evidence of recurrence for at least 3 months) that might increase the risk of bleeding.~* Estimated life expectancy \< 12 months due to a non-pulmonary cause.~* Subject has another respiratory disease that is predominant (as judged by the PI) in addition to IPF.~* Anticoagulation-related exclusions include:~  1. Current anticoagulation therapy with warfarin~ 2. Increased risk of bleeding (e.g. uncorrectable inherited or acquired bleeding disorder)~ 3. Platelet count \< 100,000 or hematocrit \< 30% or \> 55%~ 4. History of severe gastrointestinal bleeding within 6 months of screening~ 5. History of cerebral vascular accident (CVA) within 6 months of screening~ 6. High risks of falls as judged by the PI~ 7. Surgery or major trauma within the past 30 days~ 8. Pregnancy, or lack of use of birth control method in women of childbearing age~ 9. Any condition that, in the determination of the PI, is likely to require anticoagulation therapy during the study.~ 10. Clopidogrel and aspirin combination therapy for \> 30 days duration is exclusionary.~      (Aspirin monotherapy \[81-325 mg daily\] or clopidogrel monotherapy are acceptable. Combination clopidogrel and aspirin \<=81mg/day for ≤30 days is also acceptable. NSAIDS are discouraged; acetaminophen may be substituted.)~ 11. Patients on prasugrel are excluded. Prasugrel must be stopped for one week prior to starting study drug.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- warfarin (Type: ACTIVE_COMPARATOR): Oral warfarin titrated to an international normalization ratio (INR) of 2-3
- placebo (Type: PLACEBO_COMPARATOR): Oral placebo (1mg or 2.5mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).